Table 6. Summary on BRAF rate in PTC from Asian countries and regions.
| Region | Country/region | No. of studies | Year of publication | Total PTC* | BRAF-positive | BRAF rate (%) |
|---|---|---|---|---|---|---|
| East Asia | Japan | 9 | 2007–2018 | 986 | 696 | 71 |
| South Korea | 40 | 2005–2020 | 20599 | 15558 | 76 | |
| China | 51 | 2009–2019 | 15509 | 11038 | 71 | |
| Taiwan | 2 | 2005, 2013 | 157 | 81 | 52 | |
| Hong Kong | 2 | 2004, 2009 | 84 | 41 | 49 | |
| South Asia | India | 9 | 2012–2018 | 561 | 256 | 46 |
| Central Asia | Kazakhstan | 2 | 2007, 2018 | 168 | 81 | 48 |
| Middle East | Saudi Arabia | 5 | 2008–2017 | 1041 | 482 | 46 |
| Iran | 5 | 2008–2017 | 346 | 198 | 57 | |
| Iraq | 1 | 2017 | 47 | 12 | 26 | |
| Southeast Asia | Myanmar | 1 | 2017 | 44 | 10 | 23 |
| Thailand | 1 | 2020 | 476 | 290 | 61 | |
| Vietnam | 1 | 2016 | 53 | 44 | 83 | |
| Indonesia | 2 | 2013, 2016 | 94 | 34 | 36 | |
| Singapore | 2 | 2015, 2019 | 124 | 81 | 65 | |
| The Philippines | 2 | 2016, 2019 | 82 | 37 | 45 |
*, pediatric cases were excluded if indicated in the original studies (one series from Japan, China, and Saudi Arabia). PTC, papillary thyroid carcinoma.